Every novel cancer immunotherapy has its day in the limelight, although it obviously goes without saying we shouldn’t compare them unless in a head-to-head trial.
What if the comparisons are made using the wrong parameters, however?
Well, this just compounds the problem further and does neither product nor company or researchers any justice.
This time around we continue the latest chapter in an story we have been following for several years now before it was really in many people’s conscience.
Sometimes it helps to go back to the beginning to see how far things have come, other times it is more useful to look in a broader context of the space it is competing in.
In this latest installment we attempt a look at both plus offer some commentary on how it could be viewed…